GlassScriptPhysician profile
Jennifer Rajan
NPI 1477509511
$7,197.21
in general payments reported to CMS, 2019-2025
32 companies · $1,636 in 2025
The $1,636 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $592 · 2021: $593 · 2022: $978 · 2023: $1,693 · 2024: $1,153 · 2025: $1,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,368 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,367.86 |
| Education | $114.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,454.20 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $654.49 | 2019-2025 | |
| Genzyme Corporation | $577.31 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $444.48 | 2019-2024 | Ilumya, Winlevi, Absorica Ld |
| Incyte Corporation | $392.30 | 2021-2025 | Opzelura |
| Pfizer INC. | $391.58 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $348.30 | 2020-2021 | |
| Amgen INC. | $343.62 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $306.35 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $277.11 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $233.28 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $227.54 | 2019-2025 | |
| Lilly USA, LLC | $167.53 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $160.75 | 2019-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $153.11 | 2020-2025 | Anzupgo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $152.64 | 2023-2025 | Vyjuvek |
| Immunitybio, INC. | $138.72 | 2025 | |
| Myriad Genetic Laboratories, INC. | $115.53 | 2022 | |
| Almirall LLC | $96.47 | 2019-2025 | Klisyri |
| Arcutis Biotherapeutics, INC. | $92.26 | 2023-2024 | Zoryve |
| Ucb, INC. | $82.92 | 2019-2024 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $61.63 | 2019-2023 | Arazlo, Duobrii, Jublia |
| Revance Therapeutics, INC. | $58.71 | 2024 | Daxxify |
| Botanix Sb INC | $46.21 | 2025 | Sofdra |
| Journey Medical Corporation | $41.93 | 2019-2025 | |
| Sebela Pharmaceuticals INC. | $38.50 | 2019-2021 | |
| Celgene Corporation | $36.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.11 | 2024 | Spevigo |
| Dusa Pharmaceuticals, INC. | $25.56 | 2019 | |
| Kyowa Kirin, INC. | $23.17 | 2023 | Poteligeo |
| Aclaris Therapeutics, INC. | $13.23 | 2019 | |
| Genentech USA, INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Rajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.